查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2059310

神經系統診斷市場：市場洞察、競爭格局與市場預測（2034 年）

Neurodiagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

神經診斷市場概述

  • 全球神經診斷市場預計將從 2025 年的 99.1093 億美元成長到 2034 年的 185.9804 億美元，顯示其成長強勁且持續。
  • 全球神經診斷市場預計在 2026 年至 2034 年的預測期內將以 7.31% 的複合年成長率成長。
  • 神經診斷市場整體上受到癲癇、阿茲海默症和帕金森氏症等神經系統疾病盛行率上升的驅動，這顯著增加了對精準、連續腦監測解決方案的需求。同時，睡眠呼吸中止症等睡眠障礙診斷的不斷擴展也提升了對多導睡眠圖和家用診斷系統的需求。此外，隨著複雜神經外科手術的增多，術中神經生理監測的應用也不斷推進，以確保病人安全和手術精準度。人工智慧驅動的腦電圖（EEG）分析、攜帶式設備和雲端平台等技術的快速創新進一步強化了這些需求因素，提高了診斷的效率、可及性和準確性。這些趨勢共同為全球神經診斷市場創造了強勁且多元化的成長環境。
  • 在神經診斷市場中運作的主要公司包括 Natus Medical Incorporated、Nihon Kohden Corporation、Medtronic plc、Cadwell Industries、Compumedics Limited、EB Neuro SpA、Micromed SpA、Neurosoft、Deymed Diagnostic、Ambu A/S、Brain Products GmbH、Electrical Geourox Corporation、OpenBCI、Emotiv、NeuroSky 和 ​​Advanced Brain Monitoring。
  • 北美地區擁有先進的醫療基礎設施、尖端診斷技術的高普及率，以及Natus Medical Incorporated、日本光電株式會社和美敦力等行業領導者的強大影響力，預計將成為神經診斷市場的主要驅動力。該地區癲癇、阿茲海默症和帕金森氏症等神經系統疾病的高發生率也推動了對神經診斷程序的穩定需求。此外，人們對睡眠呼吸中止症等睡眠障礙的認知不斷提高、完善的保險報銷體係以及持續的研發投入，都進一步促進了市場成長，鞏固了北美地區的主導地位。
  • 在按產品類型分類的神經診斷市場中，預計到 2025 年，系統類產品將佔最大的市場佔有率。

推動神經診斷市場成長的因素

  • 神經系統疾病盛行率的上升推動了神經系統診斷需求的激增：癲癇、帕金森氏症、阿茲海默症和中風等神經系統疾病發病率的不斷攀升是神經系統診斷市場的主要驅動力。這些疾病需要持續監測和早期診斷，顯著增加了對腦電圖 (EEG)、肌電圖 (EMG) 和其他神經系統診斷測試的需求。此外，全球神經退化性疾病負擔的加重也迫使醫療系統採用先進的診斷解決方案。
  • 睡眠障礙診斷範圍的擴大：睡眠呼吸中止症和失眠等睡眠障礙的盛行率不斷上升，促使對多導睡眠圖和家用睡眠監測設備的需求增加。睡眠診斷正逐漸成為神經學診斷領域的重要分支。
  • 神經外科手術量增加：複雜神經外科和脊椎手術的增加推動了術中神經生理監測（IONM）系統的需求。這些系統透過在手術過程中持續監測神經功能，有助於降低手術風險。
  • 神經診斷系統的技術進步：持續創新，包括人工智慧驅動的腦電圖 (EEG) 分析、攜帶式和穿戴式式神經診斷設備、基於雲端的數據分析平台和先進的術中監測系統，正在提高診斷的準確性、效率和可及性，鼓勵醫療保健專業人員採用最新的神經診斷解決方案。

神經診斷市場報告細分

這份神經診斷市場報告全面概​​述了全球神經診斷市場，重點分析了關鍵趨勢、成長要素、挑戰和機會。報告按產品類型、技術、應用、最終用戶和地區進行了詳細的市場細分，並深入剖析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態。報告詳細介紹了主要產業參與企業及其最新產品創新，為企業提供關鍵數據，幫助他們識別市場潛力、制定策略規劃，並掌握快速成長的神經診斷市場中新興的機會。

神經學診斷是指一系列用於評估神經系統（包括大腦、脊髓和周邊神經）功能和健康狀況的醫學檢查和技術。這包括腦電圖 (EEG)、阿茲海默症(EMG)、神經傳導研究和睡眠診斷等技術，用於檢測、監測和管理癲癇、阿茲海默症和帕金森氏症等神經系統疾病。這些工具能夠幫助臨床醫生做出準確的診斷並制定有效的治療策略。

神經診斷市場整體上受到癲癇、阿茲海默症和帕金森氏症等神經系統疾病盛行率上升的推動，這顯著增加了急慢性醫療機構對精準、即時、連續腦監測解決方案的需求。由於這些疾病通常需要長期管理和重複評估，醫療專業人員越來越依賴腦電圖 (EEG)、肌電圖 (EMG) 和連續監測系統等先進的神經診斷工具。同時，睡眠障礙（尤其是睡眠呼吸中止症）的患病範圍不斷擴大，推動了對多導睡眠圖系統和便利家用診斷設備的需求，從而將市場拓展到醫院以外的領域。

此外，神經外科和脊椎手術日益複雜，推動了術中神經生理監測（IONM）系統的應用。這些系統透過在手術過程中即時追蹤神經功能，在降低手術風險和改善患者預後方面發揮著至關重要的作用。人工智慧驅動的腦電圖（EEG）分析、攜帶式和穿戴式式神經診斷設備以及基於雲端的數據管理平台等技術的快速發展，進一步強化了這些需求因素。這些創新提高了診斷準確性，縮短了觀察時間，並改善了偏遠和醫療資源匱乏地區的醫療服務。這些因素共同造就了一個強勁且多元化的成長環境，使神經診斷成為現代神經醫療保健的重要組成部分，並推動了全球市場的快速擴張。

神經診斷市場目前的市場動態和趨勢是什麼？

神經系統診斷市場整體上受到癲癇、阿茲海默症和帕金森氏症等神經系統疾病盛行率上升的推動，這顯著增加了對精準、連續腦部監測解決方案的需求。根據世界衛生組織（WHO，2024）提供的數據，全球每年約有500萬人被診斷出患有癲癇。

此外，根據阿茲海默症協會（2026）的數據，到2026年，美國將有超過700萬人患有阿茲海默症，預計到2050年，這一數字將接近1,300萬。在癲癇領域，需要使用腦電圖（EEG）及相關技術進行頻繁且長期的監測，以檢測異常腦部活動、控制癲癇發作並調整治療方案，這導致神經診斷系統和耗材的使用量增加。同樣，在阿茲海默症，早期發現對於改善患者預後和製定護理計劃至關重要，這促使對使用先進神經診斷工具進行早期診斷和疾病進展監測的需求增加。這兩種疾病的慢性進行性特徵使得反覆的診斷程序成為必要，從而促使神經診斷設備、軟體和耗材的普及，最終促進了市場的持續成長。

此外，睡眠障礙診斷範圍的擴大顯著推動了神經診斷市場的發展，對多導睡眠多項生理檢查（PSG）、腦電圖（EEG）睡眠分析和家用診斷設備等先進監測系統的需求不斷成長。睡眠障礙（尤其是睡眠呼吸中止症、失眠和發作性睡病）的盛行率上升，以及公眾意識的提高和篩檢力度的加強，促使醫院、睡眠檢查室和居家照護機構的診斷數量不斷增加。睡眠基金會（2025年）的數據預測，高達75%的老人會出現失眠症狀。雖然多導睡眠圖仍然是診斷的黃金標準工具，並佔了睡眠監測的大部分佔有率，但由於其便利性和易用性，家用睡眠檢測正在迅速發展。這種向持續性和分散式監測的轉變直接促進了神經診斷系統和耗材的普及。近期趨勢進一步凸顯了這一成長軌跡。 2026年1月，Empatica的EmbraceMini穿戴式裝置獲得FDA核准，用於睡眠監測和基於活動記錄器的評估，從而實現遠端連續睡眠診斷。此外，2025年6月，該公司增強了其數位健康平台，新增了先進的生理監測功能，支援睡眠和神經數據的整合。因此，預計這些因素將在預測期內推動整個神經診斷市場的成長。

然而，由於數據解讀的複雜性和嚴格的法規核准流程，神經診斷市場面臨許多限制。腦電圖（EEG）和肌電圖（EMG）等神經診斷測試會產生極其複雜且波動性極大的腦電圖數據，需要專業知識和耗時的分析，這限制了其在臨床實踐中的效率和擴充性。同時，針對神經診斷設備和軟體（尤其是那些整合人工智慧的設備）的嚴格監管要求，延長了產品開發週期，並增加了製造商的合規成本。這些因素共同作用，減緩了先進技術的應用，延緩了創新解決方案進入市場，並成為神經診斷市場整體成長的主要障礙。

神經診斷市場細分分析

按產品類型、技術、應用、最終用戶和地區分類。

神經診斷市場區域分析

北美神經診斷市場趨勢

預計到2025年，北美將佔神經診斷市場39%的最大佔有率，成為全球最大的神經診斷市場。北美擁有先進的醫療基礎設施、尖端診斷技術的普及率高，以及Natus Medical Incorporated、Nihon Kohden Corporation和Medtronic plc等領先企業的強大影響力，這些因素預計將推動神經診斷市場的發展。此外，該地區癲癇、阿茲海默症和帕金森氏症等神經系統疾病的高發生率也帶動了對神經診斷檢測的持續需求。同時，人們對睡眠呼吸中止症等睡眠障礙的認知不斷提高，完善的保險報銷體係以及持續的研發投入，都進一步促進了市場成長，鞏固了北美的主導地位。

根據美國疾病管制與預防中心（CDC，2024 年）的數據，美國約有 300 萬成年人患有癲癇。

此外，根據帕金森氏症基金會（2026年）提供的數據，美國有超過110萬人患有帕金森氏症。癲癇的診斷高度依賴腦電圖（EEG）及相關診斷工具進行癲癇發作的檢測、分類和治療管理，且通常需要反覆的長期監測，因此神經診斷系統和耗材的使用率很高。同樣，帕金森氏症作為一種進行性性神經退化性疾病，也需要透過神經生理學檢查和先進的診斷技術對大腦和運動功能進行持續評估。這兩種疾病的慢性特徵都要求頻繁的後續觀察和持續監測，從而促進了神經診斷設備、軟體和耗材的普及，最終推動了市場的持續成長。

此外，北美神經診斷市場主要受睡眠障礙診斷的擴展、神經外科手術的增加以及神經診斷系統技術的快速進步的推動，這些因素共同創造了臨床和居家照護領域的高成長環境。睡眠呼吸障礙等睡眠障礙的盛行率不斷上升，顯著增加了對睡眠多項生理檢查（PSG）系統和基於腦電圖（EEG）的睡眠分析的需求，尤其是在家庭和穿戴式診斷方式日益普及的情況下。近期的一些進展也印證了這一點，例如Beacon Biosignals公司於2024年3月獲得了FDA 510(k)認證，其基於人工智慧的睡眠分析軟體SleepStageML™能夠根據腦電圖數據自動進行睡眠分期，從而提高診斷效率。

同時，北美神經外科和脊椎手術數量的不斷成長推動了術中神經生理監測（IONM）系統的應用。這些系統高度依賴腦電圖（EEG）、肌電圖（EMG）和誘發電位技術，以確保手術的精準性和病人安全。攜帶式和人工智慧整合的神經診斷系統等技術的持續進步進一步加劇了這一需求。例如，2026年4月，FDA批准了Zeto公司的「Zeto New Wave」腦電圖系統上市510(k)。該系統具備雲端連接和整合多訊號監測功能，專為門診和家庭使用而設計，提高了醫療服務的可近性和工作效率。

進一步佐證這一趨勢的是，2024年9月，Forest Devices公司的SignalNED系統獲得FDA 510(k)認證，凸顯了北美神經系統診斷監測解決方案的持續創新。此外，諸如EB Neuro公司的BE Plus PRO和Neurotravel公司的LIGHT系統等整合式神經系統診斷平台，結合了腦電圖(EEG)、肌電圖(EMG)和多導睡眠圖(PSG)功能，也反映了市場對多功能診斷系統日益成長的需求。

總體而言，睡眠障礙負擔日益加重、外科手術干預增多，以及 FDA 對 EEG、EMG/NCS 和多導睡眠圖技術的大力批准，正在顯著加速北美地區神經診斷解決方案的採用，從而推動整體市場成長。

歐洲神經診斷市場趨勢

受神經系統疾病盛行率上升、人口老化以及對先進診斷技術投資增加的推動，歐洲神經診斷市場正經歷強勁且持續的成長。德國、英國和法國等國正面臨失智症、癲癇和中風等疾病日益沉重的負擔，這顯著提升了對腦電圖（EEG）、肌電圖（EMG）和神經影像等神經診斷技術的需求。例如，阿茲海默症基金會（2025年）的數據顯示，到2025年，歐盟27國的失智症患者人數預計居住9,065,706人，到2050年，這一數字預計將居住14,335,788人。因此，全部區域對失智症技術的需求都在增加。

此外，歐洲擁有完善的醫療保健體系、有利的政府政策以及不斷成長的神經科學領域研究經費，所有這些都有利於創新診斷解決方案的採用。該地區數位技術的融合度也在不斷提高，包括人工智慧驅動的腦電圖分析和攜帶式監測系統，進一步加速了市場成長。近期的一些進展也凸顯了這一成長趨勢。 2025年10月，Natus Medical Incorporated收購了挪威公司Holberg EEG，將人工智慧驅動的腦電圖（EEG）分析技術整合到其產品組合中。這增強了其在歐洲市場的地位，並提高了診斷的準確性。

總體而言，疾病負擔的加重、技術創新和策略性企業活動正在推動歐洲神經診斷市場強勁且持續的成長。

亞太地區神經診斷市場趨勢

亞太地區正崛起為神經診斷市場的主要驅動力，這主要得益於其龐大且快速老化的人口、癲癇、中風和帕金森氏症等神經系統疾病日益成長的患病率，以及中國、印度和日本等主要國家醫療基礎設施的不斷完善。醫療支出的增加、診斷服務可及性的提高以及人們對早期發現神經系統疾病重要性的認知不斷增強，都顯著推動了腦電圖（EEG）、肌電圖（EMG）和睡眠診斷等神經診斷系統的應用。此外，該地區正朝著攜帶式和經濟高效的診斷解決方案轉變，從而改善了都市區和郊區獲得神經診斷服務的途徑。政府旨在加強醫療體系的舉措，以及全球和區域領導者的加強投資，進一步加速了市場成長。這些因素共同促成了亞太地區成為全球神經診斷市場成長最快的地區。

神經診斷市場的主要參與者有哪些？

以下是神經診斷市場的主要參與者。這些公司通常佔最大的市場佔有率，並引領著行業趨勢。

  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Cadwell Industries
  • Compumedics Limited
  • EB Neuro SpA
  • Micromed SpA
  • Neurosoft
  • Deymed Diagnostic
  • Ambu A/S
  • Brain Products GmbH
  • Electrical Geodesics Inc. (EGI)
  • NCC Medical Co.
  • NeuroWave Systems
  • Neuroelectrics
  • Persyst Development Corporation
  • OpenBCI
  • Emotiv
  • NeuroSky
  • Advanced Brain Monitoring
  • 其他

競爭格局如何影響神經診斷市場？

神經診斷市場的競爭格局極為活躍且相對集中，其特點是大型跨國公司與新興技術主導型企業並存。西門子醫療、通用電氣醫療、飛利浦和Natus Medical等領先企業憑藉其在神經影像、腦電圖/肌電圖系統和整合診斷平台方面的強大產品系列，主導著市場。這些公司日益注重技術創新，特別是人工智慧、雲端分析和攜帶式診斷解決方案的整合，以實現產品差異化並提高臨床效率。同時，隨著各公司尋求擴展其技術能力和地理覆蓋範圍，併購和策略聯盟等手段也加劇了市場競爭。

此外，人工智慧驅動的神經診斷軟體、基於生物標記的診斷技術以及專注於穿戴式裝置的新創公司和利基參與企業的興起，正在改變傳統的以設備為中心的市場結構，迫使老牌企業轉向整合硬體、軟體和分析能力的整合式服務模式。持續的產品推出、監管批准以及研發投入進一步塑造了這種不斷變化的競爭格局，推動了診斷準確性的快速創新和提升。整體而言，競爭格局正朝著技術主導、夥伴關係共贏的生態系統轉變，企業不僅在產品上競爭，還在數位化能力、臨床結果和長期價值主張方面展開競爭。

神經診斷市場近期趨勢

  • 2026 年 4 月，FDA 批准 Zeto Inc. 的「Zeto New Wave」腦電圖系統獲得 510(k) 認證。該系統專為門診和家庭使用而設計，具有雲端連接和整合多訊號監測功能，以提高可及性和工作流程效率。
  • 2026年1月，Empatica公司的EmbraceMini獲得FDA批准，這是一款用於睡眠監測和基於活動記錄器的評估的穿戴式設備。這將實現遠端和連續的睡眠監測。

神經診斷市場的市場細分

  • 按產品類型分類的神經診斷產品市場趨勢
  • 系統
  • 腦電圖（EEG）系統
  • 肌電圖（EMG）系統
  • 神經傳導研究（NCS）系統
  • 睡眠多項生理檢查系統
  • 其他
  • 配件和耗材
  • 軟體
  • 神經診斷技術展覽
  • 神經影像技術
  • 體外診斷
  • 神經資訊學
  • 神經學診斷實踐
  • 癲癇和癲癇發作
  • 睡眠障礙
  • 中風和腦血管疾病
  • 帕金森氏症
  • 失智症和阿茲海默症
  • 其他
  • 接觸神經診斷的最終用戶
  • 醫院和神經科科診所
  • 診斷檢查室
  • 門診手術中心
  • 其他
  • 神經系統診斷的區域趨勢
  • 北美神經學診斷市場
  • 美國神經學診斷市場
  • 加拿大神經診斷市場
  • 墨西哥神經診斷市場
  • 歐洲神經診斷市場
  • 英國神經學診斷市場
  • 德國神經診斷市場
  • 法國神經診斷市場
  • 義大利神經診斷市場
  • 西班牙神經診斷市場
  • 其他歐洲神經診斷市場
  • 亞太地區神經系統診斷市場。
  • 中國神經學診斷市場
  • 日本神經診斷市場
  • 印度神經診斷市場
  • 澳洲神經診斷市場
  • 韓國神經診斷市場
  • 亞太地區其他神經學診斷市場
  • 其他區域神經學診斷市場
  • 南美洲神經診斷市場
  • 中東神經診斷市場
  • 非洲神經診斷市場

影響分析

人工智慧驅動的創新與應用：

人工智慧驅動的創新正在變革神經診斷，實現對複雜神經數據的更快、更準確、更擴充性的分析。先進的機器學習演算法正被擴大用於分析腦電圖 (EEG) 和肌電圖 (EMG) 訊號，從而實現對癲癇發作和阿茲海默症早期認知衰退等異常情況的自動檢測。人工智慧也被整合到睡眠診斷中，實現睡眠分期自動評分並識別睡眠呼吸中止症等疾病，顯著減少人工操作並提高診斷的一致性。此外，人工智慧驅動的神經影像工具正在增強檢測大腦結構和功能變化的能力，從而支持中風和神經退化性疾病等疾病的早期診斷。這些技術透過雲端平台分析大規模資料集，進一步實現了即時監測、預測分析和個人化治療方案的發展。總而言之，人工智慧正在將神經診斷轉變為一種更加自動化、精準和以患者為中心的模式，在改善臨床結果的同時，也提高了整個醫療保健系統的效率。

美國關稅對神經診斷市場的影響分析：

作為醫療設備業的一部分，美國關稅對神經診斷市場的影響顯著且極具限制性，波及成本、供應鏈和市場動態。近期訂定的關稅政策，包括將於2025年4月對美國關稅體系進行徹底改革，將對大多數醫療設備徵收約10%的進口關稅，並對個別國家徵收更高的關稅（例如，對主要貿易夥伴徵收20%至50%甚至更高），這標誌著醫療技術產品關稅環境正從歷史上的低關稅環境發生轉變。由於大多數神經診斷設備（腦電圖、肌電圖和影像設備的組件）和耗材都依賴進口，這些關稅推高了採購和製造成本，擠壓了企業的利潤空間，並最終導致醫療服務提供者承擔更高的價格。

此外，由於許多神經診斷系統依賴國際採購的組件，例如半導體和感測器，關稅正在擾亂全球供應鏈，導致生產和產品交付延遲。這迫使製造商調整籌資策略、轉向本地生產或自行承擔增加的成本，進而影響整體市場成長。而且，這些增加的成本通常會轉嫁給醫院，可能導致設備升級延遲和先進神經診斷技術的普及率降低。

但從積極的一面來看，美國關稅正在刺激國內製造業發展和供應鏈本地化，這有助於增強長期韌性並降低對進口的依賴。整體而言，雖然關稅會帶來成本上升、供應中斷和產品普及速度放緩等短期挑戰，但它們也正在重塑美國神經診斷市場的競爭格局和商業策略。

這項分析能為客戶帶來哪些好處？

  • 成本管理：透過了解關稅趨勢，客戶可以預測成本上漲，並據此調整定價策略，以確保盈利。
  • 供應鏈最佳化：透過尋找替代來源並實現供應鏈多元化，客戶可以減少對高關稅地區的依賴，增強自身抵禦能力。
  • 監管合規：專家指導幫助客戶應對不斷變化的法規環境，從而保持合規並避免潛在的法律挑戰。
  • 策略規劃：深入了解關稅的影響，使客戶能夠就製造地、夥伴關係和打入市場策略做出明智的決策。

神經診斷市場報告要點。

  • 對目前神經診斷市場規模（2025 年）及 8 年市場預測（2026 年至 2034 年）進行分析。
  • 過去三年發生的主要產品和技術開發、併購、夥伴關係和合資企業
  • 在神經診斷市場佔主導地位的領先公司。
  • 神經診斷市場的其他競爭者也面臨各種機會。
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年又會呈現哪些趨勢？
  • 目前哪些地區、國家在神經診斷市場表現最佳？
  • 企業應專注於哪些地區和國家，以尋求神經診斷市場的未來成長機會？

關於神經診斷市場的常見問題

1. 神經診斷市場的成長率是多少？

  • 預計從 2026 年到 2034 年的預測期內，神經診斷市場將以 7.31% 的複合年成長率成長。

2. 神經診斷市場的規模有多大？

  • 全球神經診斷市場預計將從 2025 年的 99.1093 億美元成長到 2034 年的 185.9804 億美元。

3. 哪個地區在神經診斷市場中佔最大的市場佔有率？

  • 北美地區擁有先進的醫療基礎設施、尖端診斷技術的高普及率，以及Natus Medical Incorporated、日本光電株式會社和美敦力等領先企業的強大影響力，預計將引領神經診斷市場的發展。該地區阿茲海默症和帕金森氏症等神經系統疾病的高發生率也推動了對神經診斷程序的穩定需求。此外，人們對睡眠呼吸中止症等睡眠障礙的認知不斷提高、完善的保險報銷體係以及對研發的持續投入，都進一步促進了市場成長，鞏固了北美地區的主導地位。

4. 神經診斷市場的成長要素為何？

  • 神經診斷市場整體上受到癲癇、阿茲海默症和帕金森氏症等神經系統疾病盛行率上升的驅動，這顯著增加了對精準、連續腦監測解決方案的需求。同時，診斷範圍的擴大，特別是睡眠呼吸中止症等睡眠障礙的診斷，推動了對多導睡眠圖和家用診斷系統的需求。此外，神經外科手術日益複雜，促使術中神經生理監測的應用，以確保病人安全和手術精準度。人工智慧驅動的腦電圖（EEG）分析、攜帶式設備和雲端平台等技術的快速發展進一步推動了這些需求因素，提高了診斷的效率、可及性和準確性。這些趨勢共同為全球神經診斷市場創造了強勁且多元化的成長環境。

5. 神經診斷市場的主要公司有哪些？

  • 神經診斷市場的主要參與者包括 Natus Medical Incorporated、Nihon Kohden Corporation、Medtronic plc、Cadwell Industries、Compumedics Limited、EB Neuro SpA、Micromed SpA、Neurosoft、Deymed Diagnostic、Ambu A/S、Brain Products GmbH、Electrical Geomocics Inc. (E.S、Acoalcoal、Necoal、Colecoal、Neuroer、Cercoal、Necoal、Ne看到、Cox Corporation、OpenBCI、Emotiv、NeuroSky 和 ​​Advanced Brain Monitoring。

目錄

第1章：神經診斷市場報告概述

第2章：神經診斷市場摘要整理

第3章：神經診斷市場關鍵因素分析

  • 推動神經診斷市場發展的因素
    • 神經系統疾病發生率上升
    • 睡眠障礙診斷範圍擴大
    • 神經外科手術數量增加
    • 神經診斷系統的技術進步
  • 阻礙神經診斷市場發展的因素與挑戰。
    • 數據解讀的複雜性
    • 產品核可的嚴格監管流程
  • 神經診斷市場的機遇
    • 人工智慧在腦電圖 (EEG) 自動分析、預測分析和神經系統疾病早期檢測方面的應用正在不斷擴展。

第4章：影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅影響分析

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：神經診斷市場波特五力競爭力分析

第7章：神經診斷市場評估

  • 依產品類型
    • 系統
    • 配件及耗材
    • 軟體
  • 透過技術
    • 神經影像技術
    • 用於體外診斷
    • 神經資訊學
  • 用途別
    • 癲癇和癲癇發作
    • 睡眠障礙
    • 中風和腦血管疾病
    • 帕金森氏症
    • 失智症和阿茲海默症
    • 其他
  • 最終用戶
    • 醫院和神經科科診所
    • 診斷檢查室
    • 門診手術中心
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章：創業資金籌措與投資趨勢

第10章：神經診斷市場中的公司與產品概況

  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc.
  • Cadwell Industries
  • Compumedics Limited
  • EB Neuro SpA
  • Micromed SpA
  • Neurosoft
  • Deymed Diagnostic
  • Ambu A/S
  • Brain Products GmbH
  • Electrical Geodesics Inc. (EGI)
  • NCC Medical Co.
  • NeuroWave Systems
  • Neuroelectrics
  • Persyst Development Corporation
  • OpenBCI
  • Emotiv
  • NeuroSky
  • Advanced Brain Monitoring

第11章：KOL的觀點

第12章 專案方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0924

Neurodiagnostics Market Summary

  • The global neurodiagnostics market is expected to increase from USD 9,910.93 million in 2025 to USD 18,598.04 million by 2034, reflecting strong and sustained growth.
  • The global neurodiagnostics market is growing at a CAGR of 7.31% during the forecast period from 2026 to 2034.
  • The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate and continuous brain monitoring solutions. At the same time, the expansion of sleep disorder diagnosis, particularly for conditions like Sleep Apnea, is boosting the demand for polysomnography and home-based diagnostic systems. Additionally, the growing number of complex neurosurgical procedures is driving the adoption of intraoperative neurophysiological monitoring to ensure patient safety and surgical precision. These demand-side factors are further amplified by rapid technological advancements such as AI-enabled EEG analysis, portable devices, and cloud-based platforms, which are improving diagnostic efficiency, accessibility, and accuracy. Together, these trends are creating a strong, multi-dimensional growth environment for the global neurodiagnostics market.
  • The leading companies operating in the neurodiagnostics market include Natus Medical Incorporated, Nihon Kohden Corporation, Medtronic plc, Cadwell Industries, Compumedics Limited, EB Neuro S.p.A., Micromed S.p.A., Neurosoft, Deymed Diagnostic, Ambu A/S, Brain Products GmbH, Electrical Geodesics Inc. (EGI), NCC Medical Co., NeuroWave Systems, Neuroelectrics, Persyst Development Corporation, OpenBCI, Emotiv, NeuroSky, Advanced Brain Monitoring, and others.
  • North America is expected to dominate the neurodiagnostics market due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of leading industry players such as Natus Medical Incorporated, Nihon Kohden Corporation, and Medtronic plc. The region also has a high prevalence of neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which drives consistent demand for neurodiagnostic procedures. Additionally, increasing awareness of sleep disorders such as Sleep Apnea, well-established reimbursement frameworks, and continuous investments in research and development further support market growth, reinforcing North America's leading position.
  • In the product type segment of the neurodiagnostics market, the systems category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Neurodiagnostics Market

  • Rising prevalence of neurological disorders leading to a surge in neurodiagnostics: The increasing incidence of neurological conditions such as Epilepsy, Parkinson's Disease, Alzheimer's Disease, and Stroke is a primary driver of the neurodiagnostics market. These conditions require continuous monitoring and early diagnosis, significantly increasing the demand for EEG, EMG, and other neurodiagnostic tests. Additionally, the growing burden of neurodegenerative diseases globally is pushing healthcare systems to adopt advanced diagnostic solutions.
  • Expansion of sleep disorder diagnosis: The rising prevalence of sleep disorders such as Sleep Apnea and insomnia has increased the demand for polysomnography and home sleep testing devices. Sleep diagnostics is becoming a major sub-segment within neurodiagnostics.
  • Increasing neurosurgical procedures: The growth in complex neurosurgeries and spinal procedures is driving the demand for intraoperative neurophysiological monitoring (IONM) systems. These systems help reduce surgical risks by continuously monitoring nerve function during procedures.
  • Technological advancements in neurodiagnostic systems: Continuous innovations such as AI-based EEG interpretation, portable and wearable neurodiagnostic devices, cloud-based data analysis platforms, and advanced intraoperative monitoring systems are improving diagnostic accuracy, efficiency, and accessibility, and encouraging healthcare providers to adopt modern neurodiagnostic solutions.

Neurodiagnostics Market Report Segmentation

This neurodiagnostics market report offers a comprehensive overview of the global neurodiagnostics market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Systems {Electroencephalography (EEG) Systems, Electromyography (EMG) Systems, Nerve Conduction Studies (NCS) Systems, Polysomnography Systems, and Others}, Accessories and Consumables, and Software), Technology (Neuroimaging Technology, In-Vitro Diagnostic, and Neuroinformatics), Application (Epilepsy and Seizure Disorders, Sleep Disorders, Stroke and Cerebrovascular Diseases, Parkinson's, Dementia and Alzheimer's, and Others), End-Users (Hospitals & Neurology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing neurodiagnostics market.

Neurodiagnostics refers to a group of medical tests and technologies used to evaluate the function and health of the nervous system, including the brain, spinal cord, and peripheral nerves. It involves techniques such as EEG, EMG, nerve conduction studies, and sleep diagnostics to detect, monitor, and manage neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease. These tools help clinicians make accurate diagnoses and guide effective treatment decisions.

The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate, real-time, and continuous brain monitoring solutions across both acute and chronic care settings. As these conditions often require long-term management and repeated assessments, healthcare providers are increasingly relying on advanced neurodiagnostic tools such as EEG, EMG, and continuous monitoring systems. At the same time, the expansion of sleep disorder diagnosis, particularly for conditions like Sleep Apnea, is boosting demand for polysomnography systems as well as convenient home-based diagnostic devices, thereby widening the market scope beyond hospital settings.

Additionally, the growing number of complex neurosurgical and spinal procedures is driving the adoption of intraoperative neurophysiological monitoring (IONM) systems, which play a critical role in reducing surgical risks and improving patient outcomes by enabling real-time nerve function tracking during surgery. These demand-side drivers are further strengthened by rapid technological advancements, including AI-enabled EEG interpretation, portable and wearable neurodiagnostic devices, and cloud-based data management platforms. Such innovations are enhancing diagnostic accuracy, reducing interpretation time, and improving accessibility in remote or underserved regions. Collectively, these factors are creating a robust, multi-dimensional growth environment, positioning neurodiagnostics as a vital component of modern neurological care and a rapidly expanding global market.

What are the latest neurodiagnostics market dynamics and trends?

The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate and continuous brain monitoring solutions. According to the data provided by the World Health Organization (2024), globally, an estimated 5 million people were diagnosed with epilepsy each year.

Additionally, according to the projections provided by the Alzheimer's Association (2026), more than 7 million Americans are living with Alzheimer's in 2026, and by 2050, this number is projected to rise to nearly 13 million. Epilepsy requires frequent and long-term monitoring through EEG and related technologies to detect abnormal brain activity, manage seizures, and adjust treatment plans, leading to high utilization of neurodiagnostic systems and consumables. Similarly, Alzheimer's disease is driving demand for early diagnosis and disease progression monitoring using advanced neurodiagnostic tools, as early detection is critical for improving patient outcomes and care planning. The chronic and progressive nature of both conditions results in repeated diagnostic procedures, thereby increasing the adoption of neurodiagnostic devices, software, and consumables, and ultimately contributing to sustained market growth.

Furthermore, the expansion of sleep disorder diagnosis is significantly boosting the neurodiagnostics market by increasing the demand for advanced monitoring systems such as polysomnography (PSG), EEG-based sleep analysis, and home-based diagnostic devices. The growing prevalence of sleep conditions, particularly sleep apnea, insomnia, and narcolepsy, along with rising awareness and screening initiatives, is leading to higher diagnostic volumes across hospitals, sleep labs, and home-care settings. According to the data provided by the Sleep Foundation (2025), up to 75% of older adults experienced symptoms of insomnia. Polysomnography remains the gold-standard diagnostic tool and accounts for a dominant share of sleep monitoring, while home sleep testing is rapidly expanding due to convenience and accessibility. This shift toward continuous and decentralized monitoring is directly increasing the adoption of neurodiagnostic systems and consumables. Recent company-specific developments further highlight this growth trend. In January 2026, Empatica received FDA clearance for its EmbraceMini wearable device designed for sleep monitoring and actigraphy-based assessment, enabling remote and continuous sleep diagnostics. Additionally, in June 2025, the company enhanced its digital health platform with advanced physiological monitoring capabilities, supporting sleep and neurological data integration. Thus, the factors mentioned above are expected to boost the overall market of neurodiagnostics during the forecast period.

However, the neurodiagnostics market faces significant constraints due to the combined impact of complexity in data interpretation and stringent regulatory approval processes. Neurodiagnostic tests such as EEG and EMG generate highly complex and variable brain signal data, requiring specialized expertise and time-intensive analysis, which can limit efficiency and scalability in clinical settings. At the same time, strict regulatory requirements for the approval of neurodiagnostic devices and software, especially those incorporating AI, prolong product development timelines and increase compliance costs for manufacturers. Together, these factors slow down the adoption of advanced technologies, delay market entry of innovative solutions, and act as key barriers to the overall growth of the neurodiagnostics market.

Neurodiagnostics Market Segment Analysis

Neurodiagnostics Market by Product Type (Systems {Electroencephalography (EEG) Systems, Electromyography (EMG) Systems, Nerve Conduction Studies (NCS) Systems, Polysomnography Systems, and Others}, Accessories and Consumables, and Software), Technology (Neuroimaging Technology, In-Vitro Diagnostic, and Neuroinformatics), Application (Epilepsy and Seizure Disorders, Sleep Disorders, Stroke and Cerebrovascular Diseases, Parkinson's, Dementia and Alzheimer's, and Others), End-Users (Hospitals & Neurology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Neurodiagnostics Market Regional Analysis

North America Neurodiagnostics Market Trends

North America is expected to account for the highest proportion of 39% of the neurodiagnostics market in 2025, out of all regions. North America is expected to dominate the neurodiagnostics market due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of leading industry players such as Natus Medical Incorporated, Nihon Kohden Corporation, and Medtronic plc. The region also has a high prevalence of neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which drives consistent demand for neurodiagnostic procedures. Additionally, increasing awareness of sleep disorders such as Sleep Apnea, well-established reimbursement frameworks, and continuous investments in research and development further support market growth, reinforcing North America's leading position.

According to the data provided by the Centre for Disease Control and Prevention (2024), almost 3 million U.S. adults have epilepsy.

Additionally, as per the data provided by the Parkinson's Foundation (2026), Parkinson's disease affected more than 1.1 million people in the U.S. Epilepsy relies heavily on EEG and related diagnostic tools for seizure detection, classification, and treatment management, often requiring repeated and prolonged monitoring, which drives high utilization of neurodiagnostic systems and consumables. Similarly, Parkinson's disease, being a progressive neurodegenerative disorder, requires ongoing assessment of brain function and motor activity through neurophysiological tests and advanced diagnostic techniques. The chronic nature of both conditions leads to frequent follow-ups and continuous monitoring, thereby increasing the adoption of neurodiagnostic devices, software, and consumables, ultimately contributing to sustained market growth.

Additionally, the neurodiagnostics market in North America is being strongly driven by the expansion of sleep disorder diagnosis, increasing neurosurgical procedures, and rapid technological advancements in neurodiagnostic systems, collectively creating a high-growth environment across clinical and home-care settings. The rising prevalence of sleep disorders such as sleep apnea is significantly increasing the demand for polysomnography (PSG) systems and EEG-based sleep analysis, particularly with the shift toward home-based and wearable diagnostics. This is evident from recent developments, such as in March 2024, Beacon Biosignals received FDA 510(k) clearance for its SleepStageML(TM) AI-based sleep analysis software, which automates sleep staging from EEG data and improves diagnostic efficiency.

At the same time, the increasing volume of neurosurgical and spinal procedures in North America is driving the adoption of intraoperative neurophysiological monitoring (IONM) systems, which rely heavily on EEG, EMG, and evoked potential technologies to ensure surgical precision and patient safety. This demand is further amplified by continuous technological advancements, including portable and AI-integrated neurodiagnostic systems. For instance, in April 2026, the FDA granted 510(k) clearance to Zeto Inc. for its "Zeto New Wave" EEG system, designed for outpatient and home-based use with cloud connectivity and integrated multi-signal monitoring capabilities, improving accessibility and workflow efficiency.

Further supporting this trend, in September 2024, Forest Devices received FDA 510(k) approval for its SignalNED system, highlighting continued innovation in neurodiagnostic monitoring solutions across North America. Moreover, integrated neurodiagnostic platforms such as EB Neuro's BE Plus PRO and Neurotravel LIGHT systems combine EEG, EMG, and polysomnography capabilities, reflecting the growing demand for multi-functional diagnostic systems.

Collectively, the rising burden of sleep disorders, increasing surgical interventions, and a strong pipeline of FDA approvals across EEG, EMG/NCS, and polysomnography technologies are significantly accelerating the adoption of neurodiagnostic solutions in North America, thereby driving overall market growth.

Europe Neurodiagnostics Market Trend

The neurodiagnostics market in Europe is witnessing strong and sustained growth, driven by the rising prevalence of neurological disorders, an aging population, and increasing investments in advanced diagnostic technologies. Countries such as Germany, the UK, and France are experiencing a growing burden of conditions like dementia, epilepsy, and stroke, which is significantly increasing the demand for neurodiagnostic procedures such as EEG, EMG, and neuroimaging. For instance, according to the data provided by the Alzheimer's Foundation (2025), in 2025, an estimated 9,065,706 people with dementia lived in EU27 countries, and by 2050, an estimated 14,335,788 people with dementia will live in EU27 countries. Thus, there is a growing demand for neurodiagnostic technologies across the region.

Additionally, Europe benefits from well-established healthcare systems, favorable government initiatives, and expanding research funding in neuroscience, all of which are supporting the adoption of innovative diagnostic solutions. The region is also seeing increasing integration of digital technologies, including AI-based EEG analysis and portable monitoring systems, further accelerating market expansion. Recent developments further highlight this growth trajectory. In October 2025, Natus Medical Incorporated acquired Norway-based Holberg EEG to integrate AI-driven EEG interpretation technology into its portfolio, strengthening its presence in the European market and enhancing diagnostic accuracy.

Collectively, the combination of increasing disease burden, technological innovation, and strategic company activities is driving strong and sustained growth of the neurodiagnostics market across Europe.

Asia-Pacific Neurodiagnostics Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the neurodiagnostics market due to its large and rapidly aging population, rising prevalence of neurological disorders such as Epilepsy, Stroke, and Parkinson's Disease, and improving healthcare infrastructure across key countries like China, India, and Japan. Increasing healthcare expenditure, expanding access to diagnostic services, and growing awareness about early detection of neurological conditions are significantly boosting the adoption of neurodiagnostic systems such as EEG, EMG, and sleep diagnostics. Additionally, the region is witnessing a shift toward portable and cost-effective diagnostic solutions, making neurodiagnostics more accessible in both urban and semi-urban areas. Government initiatives aimed at strengthening healthcare systems, along with rising investments by global and regional players, are further accelerating market growth. Collectively, these factors are positioning APAC as the fastest-growing region in the global neurodiagnostics market.

Who are the major players in the neurodiagnostics market?

The following are the leading companies in the neurodiagnostics market. These companies collectively hold the largest market share and dictate industry trends.

  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Cadwell Industries
  • Compumedics Limited
  • EB Neuro S.p.A.
  • Micromed S.p.A.
  • Neurosoft
  • Deymed Diagnostic
  • Ambu A/S
  • Brain Products GmbH
  • Electrical Geodesics Inc. (EGI)
  • NCC Medical Co.
  • NeuroWave Systems
  • Neuroelectrics
  • Persyst Development Corporation
  • OpenBCI
  • Emotiv
  • NeuroSky
  • Advanced Brain Monitoring
  • Others

How is the competitive landscape shaping the neurodiagnostics market?

The competitive landscape of the neurodiagnostics market is highly dynamic and moderately consolidated, characterized by the presence of large global players alongside emerging technology-focused companies. Major companies such as Siemens Healthineers, GE HealthCare, Philips, and Natus Medical dominate the market by leveraging strong product portfolios in neuroimaging, EEG/EMG systems, and integrated diagnostic platforms. These players are increasingly focusing on technological innovation, particularly AI integration, cloud-based analytics, and portable diagnostic solutions, to differentiate their offerings and enhance clinical efficiency. At the same time, the market is witnessing intensifying competition through mergers, acquisitions, and strategic partnerships, as companies aim to expand their technological capabilities and geographic presence.

Additionally, the rise of start-ups and niche players specializing in AI-driven neurodiagnostic software, biomarker-based diagnostics, and wearable devices is disrupting the traditional device-centric market, pushing established companies to shift toward integrated, service-based models that combine hardware, software, and ana This evolving competition is further shaped by continuous product launches, regulatory approvals, and R&D investments, leading to rapid innovation and improved diagnostic accuracy. Overall, the competitive landscape is moving toward a technology-driven, partnership-oriented ecosystem, where companies compete not only on products but also on digital capabilities, clinical outcomes, and long-term value delivery.

Recent Developmental Activities in the Neurodiagnostics Market

  • In April 2026, the FDA granted 510(k) clearance to Zeto Inc. for its "Zeto New Wave" EEG system, designed for outpatient and home-based use with cloud connectivity and integrated multi-signal monitoring capabilities, improving accessibility and workflow efficiency.
  • In January 2026, Empatica received FDA clearance for its EmbraceMini wearable device designed for sleep monitoring and actigraphy-based assessment, enabling remote and continuous sleep diagnostics.

Neurodiagnostics Market Segmentation

  • Neurodiagnostics by Product Type Exposure
  • System
  • Electroencephalography (EEG) Systems
  • Electromyography (EMG) Systems
  • Nerve Conduction Studies (NCS) Systems
  • Polysomnography Systems
  • Others
  • Accessories & Consumables
  • Software
  • Neurodiagnostics Technology Exposure
  • Neuroimaging Technology
  • In-Vitro Diagnostic
  • Neuroinformatics
  • Neurodiagnostics Application Exposure
  • Epilepsy and Seizure Disorders
  • Sleep Disorders
  • Stroke and Cerebrovascular Diseases
  • Parkinson's
  • Dementia and Alzheimer's
  • Others
  • Neurodiagnostics End-Users Exposure
  • Hospitals & Neurology Clinics
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • Others
  • Neurodiagnostics Geography Exposure
  • North America Neurodiagnostics Market
  • United States Neurodiagnostics Market
  • Canada Neurodiagnostics Market
  • Mexico Neurodiagnostics Market
  • Europe Neurodiagnostics Market
  • United Kingdom Neurodiagnostics Market
  • Germany Neurodiagnostics Market
  • France Neurodiagnostics Market
  • Italy Neurodiagnostics Market
  • Spain Neurodiagnostics Market
  • Rest of Europe Neurodiagnostics Market
  • Asia-Pacific Neurodiagnostics Market
  • China Neurodiagnostics Market
  • Japan Neurodiagnostics Market
  • India Neurodiagnostics Market
  • Australia Neurodiagnostics Market
  • South Korea Neurodiagnostics Market
  • Rest of Asia-Pacific Neurodiagnostics Market
  • Rest of the World Neurodiagnostics Market
  • South America Neurodiagnostics Market
  • Middle East Neurodiagnostics Market
  • Africa Neurodiagnostics Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are transforming neurodiagnostics by enabling faster, more accurate, and scalable analysis of complex neurological data. Advanced machine learning algorithms are increasingly used to interpret EEG and EMG signals, allowing automated detection of abnormalities such as seizures in Epilepsy and early cognitive decline associated with Alzheimer's Disease. AI is also being integrated into sleep diagnostics to automate sleep stage scoring and identify disorders like Sleep Apnea, significantly reducing manual workload and improving consistency. In addition, AI-driven neuroimaging tools enhance the detection of structural and functional brain changes, supporting early diagnosis of conditions such as Stroke and neurodegenerative diseases. These technologies are further enabling real-time monitoring, predictive analytics, and personalized treatment planning by analyzing large datasets through cloud-based platforms. Overall, AI is shifting neurodiagnostics toward a more automated, precise, and patient-centric approach, improving clinical outcomes while increasing efficiency across healthcare systems.

U.S. Tariff Impact Analysis on Neurodiagnostics Market:

The U.S. tariff impact on the neurodiagnostics market, as part of the broader medical device industry, has been significant and largely restrictive, influencing costs, supply chains, and market dynamics. Recent tariff policies, including the April 2025 U.S. tariff overhaul, introduced a baseline ~10% import duty on most medical devices, with higher country-specific tariffs (e.g., up to 20%-50%+ for key trading partners), marking a shift from the historically low-duty environment for medtech products. Since a large proportion of neurodiagnostic equipment (such as EEG, EMG, and imaging components) and consumables are imported, these tariffs have increased procurement and manufacturing costs, putting pressure on margins for companies and raising prices for healthcare providers.

Additionally, tariffs are disrupting global supply chains, as many neurodiagnostic systems rely on internationally sourced components such as semiconductors and sensors, leading to delays in production and product availability. This has forced manufacturers to reconsider sourcing strategies, shift toward localized production, or absorb higher costs, impacting overall market growth. Furthermore, higher costs are often passed on to hospitals, potentially delaying equipment upgrades and reducing adoption rates of advanced neurodiagnostic technologies.

However, on the positive side, U.S. tariffs are also encouraging domestic manufacturing and supply chain localization, which may strengthen long-term resilience and reduce dependency on imports. Overall, while tariffs are creating short-term challenges such as cost inflation, supply disruptions, and slowed adoption, they are simultaneously reshaping the competitive landscape and operational strategies within the U.S. neurodiagnostics market.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the neurodiagnostics market report study

  • Market size analysis for the current neurodiagnostics market size (2025), and market forecast for 8 years (2026 to 2034)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the neurodiagnostics market.
  • Various opportunities available for the other competitors in the neurodiagnostics market space.
  • What are the top-performing segments in 2025? How these segments will perform in 2034?
  • Which are the top-performing regions and countries in the current neurodiagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the neurodiagnostics market growth in the future.

Frequently Asked Questions for the Neurodiagnostics Market

1. What is the growth rate of the neurodiagnostics market?

  • The neurodiagnostics market is estimated to grow at a CAGR of 7.31% during the forecast period from 2026 to 2034.

2. What is the market for neurodiagnostics?

  • The global neurodiagnostics market is expected to increase from USD 9,910.93 million in 2025 to USD 18,598.04 million by 2034.

3. Which region has the highest share in the neurodiagnostics market?

  • North America is expected to dominate the neurodiagnostics market due to its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and strong presence of leading industry players such as Natus Medical Incorporated, Nihon Kohden Corporation, and Medtronic plc. The region also has a high prevalence of neurological conditions like Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which drives consistent demand for neurodiagnostic procedures. Additionally, increasing awareness of sleep disorders such as Sleep Apnea, well-established reimbursement frameworks, and continuous investments in research and development further support market growth, reinforcing North America's leading position.

4. What are the drivers for the neurodiagnostics market?

  • The neurodiagnostics market is being collectively driven by the rising prevalence of neurological disorders such as Epilepsy, Alzheimer's Disease, and Parkinson's Disease, which is significantly increasing the need for accurate and continuous brain monitoring solutions. At the same time, the expansion of sleep disorder diagnosis, particularly for conditions like Sleep Apnea, is boosting the demand for polysomnography and home-based diagnostic systems. Additionally, the growing number of complex neurosurgical procedures is driving the adoption of intraoperative neurophysiological monitoring to ensure patient safety and surgical precision. These demand-side factors are further amplified by rapid technological advancements such as AI-enabled EEG analysis, portable devices, and cloud-based platforms, which are improving diagnostic efficiency, accessibility, and accuracy. Together, these trends are creating a strong, multi-dimensional growth environment for the global neurodiagnostics market.

5. Who are the key players operating in the neurodiagnostics market?

  • Some of the key market players operating in the neurodiagnostics market include Natus Medical Incorporated, Nihon Kohden Corporation, Medtronic plc, Cadwell Industries, Compumedics Limited, EB Neuro S.p.A., Micromed S.p.A., Neurosoft, Deymed Diagnostic, Ambu A/S, Brain Products GmbH, Electrical Geodesics Inc. (EGI), NCC Medical Co., NeuroWave Systems, Neuroelectrics, Persyst Development Corporation, OpenBCI, Emotiv, NeuroSky, Advanced Brain Monitoring, and others.

Table of Contents

1. Neurodiagnostics Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Neurodiagnostics Market Executive Summary

  • 2.1 Market at Glance

3. Neurodiagnostics Market Key Factors Analysis

  • 3.1 Neurodiagnostics Market Drivers
    • 3.1.1 Rising prevalence of neurological disorders
    • 3.1.2 Expansion of sleep disorder diagnosis
    • 3.1.3 Increasing neurosurgical procedures
    • 3.1.4 Technological advancements in neurodiagnostic systems
  • 3.2 Neurodiagnostics Market Restraints and Challenges
    • 3.2.1 Complexity in data interpretation
    • 3.2.2 Stringent regulatory process for product approval
  • 3.3 Neurodiagnostics Market Opportunity
    • 3.3.1 Growing adoption of artificial intelligence for automated EEG interpretation, predictive analytics, and early detection of neurological conditions

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Neurodiagnostics Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Neurodiagnostics Market Assessment

  • 7.1 By Product Type
    • 7.1.1 System
      • 7.1.1.1 Electroencephalography (EEG) Systems
      • 7.1.1.2 Electromyography (EMG) Systems
      • 7.1.1.3 Nerve Conduction Studies (NCS) Systems
      • 7.1.1.4 Polysomnography Systems
      • 7.1.1.5 Others
    • 7.1.2 Accessories & Consumables
    • 7.1.3 Software
  • 7.2 By Technology
    • 7.2.1 Neuroimaging Technology
    • 7.2.2 In-Vitro Diagnostic
    • 7.2.3 Neuroinformatics
  • 7.3 By Application
    • 7.3.1 Epilepsy and Seizure Disorders
    • 7.3.2 Sleep Disorders
    • 7.3.3 Stroke and Cerebrovascular Diseases
    • 7.3.4 Parkinson's
    • 7.3.5 Dementia and Alzheimer's
    • 7.3.6 Others
  • 7.4 By End-Users
    • 7.4.1 Hospitals & Neurology Clinics
    • 7.4.2 Diagnostic Laboratories
    • 7.4.3 Ambulatory Surgical Centers
    • 7.4.4 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.1.2 Canada Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.1.3 Mexico Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.2 Europe
      • 7.5.2.1 France Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.2.2 Germany Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.2.3 United Kingdom Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.2.4 Italy Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.2.5 Spain Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.2.6 Rest of Europe Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.3.2 Japan Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.3.3 India Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.3.4 Australia Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.3.5 South Korea Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.3.6 Rest of Asia-Pacific Neurodiagnostics Market Size in USD million (2023-2034)
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 Middle East Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.4.2 Africa Neurodiagnostics Market Size in USD million (2023-2034)
      • 7.5.4.3 South America Neurodiagnostics Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Neurodiagnostics Market Company and Product Profiles

  • 10.1 Natus Medical Incorporated
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 Nihon Kohden Corporation
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 Medtronic plc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Cadwell Industries
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 Compumedics Limited
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 EB Neuro S.p.A.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 Micromed S.p.A.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Neurosoft
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Deymed Diagnostic
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 Ambu A/S
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Brain Products GmbH
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 Electrical Geodesics Inc. (EGI)
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 NCC Medical Co.
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 NeuroWave Systems
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 Neuroelectrics
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Persyst Development Corporation
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 OpenBCI
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 Emotiv
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 NeuroSky
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 Advanced Brain Monitoring
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Neurodiagnostics Market in Global (2023-2034)
  • Table 2: Neurodiagnostics Market in Global by Product Type (2023-2034)
  • Table 3: Neurodiagnostics Market in Global by Technology (2023-2034)
  • Table 4: Neurodiagnostics Market in Global by Application (2023-2034)
  • Table 5: Neurodiagnostics Market in Global by End-Users (2023-2034)
  • Table 6: Neurodiagnostics Market in Global by Geography (2023-2034)
  • Table 7: Neurodiagnostics Market in North America (2023-2034)
  • Table 8: Neurodiagnostics Market in the United States (2023-2034)
  • Table 9: Neurodiagnostics Market in Canada (2023-2034)
  • Table 10: Neurodiagnostics Market in Mexico (2023-2034)
  • Table 11: Neurodiagnostics Market in Europe (2023-2034)
  • Table 12: Neurodiagnostics Market in France (2023-2034)
  • Table 13: Neurodiagnostics Market in Germany (2023-2034)
  • Table 14: Neurodiagnostics Market in United Kingdom (2023-2034)
  • Table 15: Neurodiagnostics Market in Italy (2023-2034)
  • Table 16: Neurodiagnostics Market in Spain (2023-2034)
  • Table 17: Neurodiagnostics Market in the Rest of Europe (2023-2034)
  • Table 18: Neurodiagnostics Market in Asia-Pacific (2023-2034)
  • Table 19: Neurodiagnostics Market in China (2023-2034)
  • Table 20: Neurodiagnostics Market in Japan (2023-2034)
  • Table 21: Neurodiagnostics Market in India (2023-2034)
  • Table 22: Neurodiagnostics Market in Australia (2023-2034)
  • Table 23: Neurodiagnostics Market in South Korea (2023-2034)
  • Table 24: Neurodiagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Table 25: Neurodiagnostics Market in the Rest of the World (2023-2034)
  • Table 26: Neurodiagnostics Market in the Middle East (2023-2034)
  • Table 27: Neurodiagnostics Market in Africa (2023-2034)
  • Table 28: Neurodiagnostics Market in South America (2023-2034)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding & Investment Trends

List of Figures

  • Figure 1: Neurodiagnostics Market Drivers
  • Figure 2: Neurodiagnostics Market Restraints
  • Figure 3: Neurodiagnostics Market Opportunities
  • Figure 4: AI-Powered Innovations in the Neurodiagnostics Market
  • Figure 5: US Tariff Impact on the Neurodiagnostics Market
  • Figure 6: Regulatory Analysis (US, EU, Japan, China)
  • Figure 7: Porter's Five Forces Analysis
  • Figure 8: Competitive Analysis
  • Figure 9: Neurodiagnostics Market in Global (2023-2034)
  • Figure 10: Neurodiagnostics Market in Global by Product Type (2023-2034)
  • Figure 11: Neurodiagnostics Market in Global by Technology (2023-2034)
  • Figure 12: Neurodiagnostics Market in Global by Application (2023-2034)
  • Figure 13: Neurodiagnostics Market in Global by End-Users (2023-2034)
  • Figure 14: Neurodiagnostics Market in Global by Geography (2023-2034)
  • Figure 15: Neurodiagnostics Market in North America (2023-2034)
  • Figure 16: Neurodiagnostics Market in the United States (2023-2034)
  • Figure 17: Neurodiagnostics Market in Canada (2023-2034)
  • Figure 18: Neurodiagnostics Market in Mexico (2023-2034)
  • Figure 19: Neurodiagnostics Market in Europe (2023-2034)
  • Figure 20: Neurodiagnostics Market in France (2023-2034)
  • Figure 21: Neurodiagnostics Market in Germany (2023-2034)
  • Figure 22: Neurodiagnostics Market in United Kingdom (2023-2034)
  • Figure 23: Neurodiagnostics Market in Italy (2023-2034)
  • Figure 24: Neurodiagnostics Market in Spain (2023-2034)
  • Figure 25: Neurodiagnostics Market in the Rest of Europe (2023-2034)
  • Figure 26: Neurodiagnostics Market in Asia-Pacific (2023-2034)
  • Figure 27: Neurodiagnostics Market in China (2023-2034)
  • Figure 28: Neurodiagnostics Market in Japan (2023-2034)
  • Figure 29: Neurodiagnostics Market in India (2023-2034)
  • Figure 30: Neurodiagnostics Market in Australia (2023-2034)
  • Figure 31: Neurodiagnostics Market in South Korea (2023-2034)
  • Figure 32: Neurodiagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Figure 33: Neurodiagnostics Market in the Rest of the World (2023-2034)
  • Figure 34: Neurodiagnostics Market in the Middle East (2023-2034)
  • Figure 35: Neurodiagnostics Market in Africa (2023-2034)
  • Figure 36: Neurodiagnostics Market in South America (2023-2034)
  • Figure 39: Competitive Landscape
  • Figure 40: Startup Funding & Investment Trends